Showing results (71-80 of 222) with videos related to
Sort By:
Pageof 23
Expert Opinion on Investigational Drugs|May 5, 2017
Atrasentan for the treatment of diabetic nephropathyJesus Egido, Jorge Rojas-Rivera, Sebastian Mas, et al.Antioxidants & Redox Signaling|August 24, 2005
Angiotensin II regulates vascular endothelial growth factor via hypoxia-inducible factor-1alpha induction and redox mechanisms in the kidneyElsa Sánchez-López, Andrés Felipe López, Vanesa Esteban, et al.Journal of the American Society of Nephrology : JASN|June 1, 2002
Angiotensin II increases parathyroid hormone-related protein (PTHrP) and the type 1 PTH/PTHrP receptor in the kidneyOscar Lorenzo, Marta Ruiz-Ortega, Pedro Esbrit, et al.Basic Research in Cardiology|January 22, 2015
Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in miceCarlota Recio, Ainhoa Oguiza, Beñat Mallavia, et al.American Heart Journal|April 24, 2012
Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis studyPayman Zamani, Peter Ganz, Peter Libby, et al.The American Journal of Cardiology|February 9, 2013
Comparison of clinical characteristics and outcomes of cardiac arrest survivors having versus not having coronary angiographyStephen W Waldo, Ehrin J Armstrong, Ameya Kulkarni, et al.Atherosclerosis|March 30, 2007
Improved characterization of atherosclerotic plaques by gadolinium contrast during intravascular magnetic resonance imaging of human arteriesEric Larose, Scott Kinlay, Andrew P Selwyn, et al.Current Opinion in Cardiology|November 5, 2003
Prediction of sites of coronary atherosclerosis progression: In vivo profiling of endothelial shear stress, lumen, and outer vessel wall characteristics to predict vascular behaviorPeter H Stone, Ahmet Umit Coskun, Yerem Yeghiazarians, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|November 10, 2007
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL studyScott Kinlay, Gregory G Schwartz, Anders G Olsson, et al.Circulation|July 21, 2004
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) StudyScott Kinlay, Gregory G Schwartz, Anders G Olsson, et al.Pageof 23